174 related articles for article (PubMed ID: 24912797)
1. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.
Bihorel S; Fiedler-Kelly J; Ludwig E; Sloan-Lancaster J; Raddad E
AAPS J; 2014 Sep; 16(5):1009-17. PubMed ID: 24912797
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes.
Sloan-Lancaster J; Abu-Raddad E; Polzer J; Miller JW; Scherer JC; De Gaetano A; Berg JK; Landschulz WH
Diabetes Care; 2013 Aug; 36(8):2239-46. PubMed ID: 23514733
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.
Kretsos K; Golor G; Jullion A; Hickling M; McCabe S; Shaw S; Jose J; Oliver R
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):388-95. PubMed ID: 27129012
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Othman AA; Tran JQ; Tang MT; Dutta S
Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic model of human insulin following different routes of administration.
Potocka E; Baughman RA; Derendorf H
J Clin Pharmacol; 2011 Jul; 51(7):1015-24. PubMed ID: 20940337
[TBL] [Abstract][Full Text] [Related]
9. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus.
Hartmann S; Biliouris K; Naik H; Rabah D; Stevenson L; Shen C; Nestorov IA; Lesko LJ; Trame MN
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):255-266. PubMed ID: 32335844
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
11. Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes.
Williams JH; Udata C; Ganguly BJ; Bucktrout SL; Joh T; Shannon M; Wong GY; Levisetti M; Garzone PD; Meng X
AAPS J; 2020 Jan; 22(2):23. PubMed ID: 31900603
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
13. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
[TBL] [Abstract][Full Text] [Related]
14. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine.
Kielbasa W; Quinlan T
J Clin Pharmacol; 2020 Feb; 60(2):229-239. PubMed ID: 31482569
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
Mitchell E; Jones G
Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.
Zhang X; Georgy A; Rowell L
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):443-55. PubMed ID: 23547848
[TBL] [Abstract][Full Text] [Related]
19. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab.
Nakashima Y; Kondo M; Miyahara H; Iwamoto Y
Drug Des Devel Ther; 2014; 8():913-9. PubMed ID: 25045250
[TBL] [Abstract][Full Text] [Related]
20. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T
Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
